|
Total number
|
2590
|
1167
|
|
Sex, men (%)
|
1827 (71)
|
838 (72)
|
|
Age, mean (sd)
|
44 (13.2)
|
44 (12.8)
|
|
Disease duration
|
16 (12.3)
|
16 (11.8)
|
|
csDMARD (concomitant use), n (%)
|
634 (24)
|
384 (33)
|
|
NSAID (concomitant use), n (%)
|
2136 (82)
|
972 (83)
|
|
Peripheral diseasea
|
464 (18)
|
195 (17)
|
|
Type of TNFi
|
|
Infliximab, n (%)
|
910 (35)
|
478 (41)
|
|
Adalimumab, n (%)
|
782 (30)
|
405 (35)
|
|
Golimumab, n (%)
|
329 (13)
|
9 (1)
|
|
Etanercept, n (%)
|
483 (19)
|
273 (23)
|
|
Certolizumab pegol, n (%)
|
86 (3)
|
2 (0)
|
|
Extra-articular SpA manifestations
|
|
Anterior uveitis, n (%)
|
711 (27)
|
308 (26)
|
|
Psoriasis, n (%)
|
156 (6)
|
65 (6)
|
|
Inflammatory bowel disease, n (%)
|
179 (7)
|
95 (8)
|
